- Molecular NameDexrazoxane
- SynonymDesrazoxane; Dexrazoxano [INN-Spanish]; Dexrazoxanum [INN-Latin]; Dextrorazoxane; Razoxana [INN-Spanish]; Razoxanum [INN-Latin]
- Weight268.273
- Drugbank_IDDB00380
- ACS_NO24584-09-6
- Show 3D model
- LogP (experiment)-2.135
- LogP (predicted, AB/LogP v2.0)-1.91
- pka2.1
- LogD (pH=7, predicted)-1.91
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.57
- LogSw (predicted, AB/LogsW2.0)1049.37
- Sw (mg/ml) (predicted, ACD/Labs)1000.0
- No.of HBond Donors2
- No.of HBond Acceptors8
- No.of Rotatable Bonds3
- TPSA98.82
- StatusFDA approved
- AdministrationN/A
- PharmacologyA cardioprotective agent.
- Absorption_valueN/A
- Absorption (description)IV administration results in complete bioavailability.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding2.0
- Volume of distribution (VD)22.0~22.4 L/m2 (or 0.5 to 1.3 L/kg), tends to be higher in children compared with adults.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHydrolysed, by dihydropyrimidine amidohydrolase (DHPase) to 1-ring and 2-ring open EDTA (ethylenediamminetetra-acetate)-like products. Metabolites (active) include a diacid–diamide cleavage product and the two monoacid–monoamide ring products.
- Half life2.1~2.5 h
- ExcretionDexrazoxane is excreted in urine as the unchanged drug and the metabolites. Approximately 42% of a dose is recovered in urine.
- Urinary ExcretionN/A
- Clerance6.25~7.88 L/h/m2, tends to be higher in children than adults.
- ToxicityHaematological toxicity can occur, caused by chemotherapy, but is more common in dexrazoxane-treated patients. Dose-limiting leucopenia has been observed with doses > 4000 mg/m2 dexrazoxane (on its own) but there is no evidence of cumulative toxicity.
- LD50 (rat)Intravenous, dog LD10 = 2 gm/kg.
- LD50 (mouse)Intraperitoneal, mouse LD10 = 500 mg/kg